Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has received a consensus rating of “Buy” from the sixteen ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, thirteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $128.77.
Several brokerages have commented on DNTH. Citigroup assumed coverage on Dianthus Therapeutics in a report on Friday, September 4th. They set a “buy” rating and a $156.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Raymond James Financial restated a “strong-buy” rating and set a $134.00 price objective on shares of Dianthus Therapeutics in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $158.00 price objective on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Finally, Truist Financial upped their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th.
Read Our Latest Stock Report on Dianthus Therapeutics
Insiders Place Their Bets
In other news, EVP Simrat Randhawa sold 23,124 shares of Dianthus Therapeutics stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total value of $2,460,624.84. Following the completion of the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $425,640. This trade represents a 85.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Simon Read sold 2,778 shares of Dianthus Therapeutics stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total value of $326,553.90. Following the completion of the transaction, the director directly owned 2,778 shares of the company’s stock, valued at approximately $326,553.90. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 45,902 shares of company stock worth $4,814,779. Company insiders own 3.02% of the company’s stock.
Institutional Investors Weigh In On Dianthus Therapeutics
Large investors have recently bought and sold shares of the stock. ABS Investment Management LLC purchased a new position in Dianthus Therapeutics in the 2nd quarter valued at approximately $194,960,000. Fifth Third Bancorp boosted its position in shares of Dianthus Therapeutics by 23.6% in the third quarter. Fifth Third Bancorp now owns 676 shares of the company’s stock valued at $60,000 after acquiring an additional 129 shares during the period. PNC Financial Services Group Inc. grew its stake in Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after acquiring an additional 139 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in Dianthus Therapeutics by 4.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 4,851 shares of the company’s stock valued at $428,000 after acquiring an additional 209 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in Dianthus Therapeutics by 83.6% in the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock worth $49,000 after purchasing an additional 254 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.
Dianthus Therapeutics Stock Performance
Shares of NASDAQ:DNTH opened at $86.03 on Monday. Dianthus Therapeutics has a 52 week low of $34.29 and a 52 week high of $117.88. The firm has a market cap of $4.71 billion, a PE ratio of -21.56 and a beta of 1.47. The firm’s fifty day moving average is $90.05 and its 200-day moving average is $85.57.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.13. The business had revenue of $1.21 million during the quarter, compared to the consensus estimate of $0.46 million. Dianthus Therapeutics had a negative return on equity of 19.68% and a negative net margin of 7,436.50%. Sell-side analysts forecast that Dianthus Therapeutics will post -3.60 EPS for the current year.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease.
Recommended Stories
- Five stocks we like better than Dianthus Therapeutics
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
